Acumen Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Acumen Pharmaceuticals's earnings have been declining at an average annual rate of -8.7%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 140.9% per year.
Key information
-8.7%
Earnings growth rate
75.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -140.9% |
| Return on equity | -19.6% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?
Apr 21
Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth
Sep 21We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
Feb 01Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
Oct 16Acumen Pharma at 11-month high on rivals’ Alzheimer’s data
Sep 28Acumen Pharmaceuticals initiated at buy at H.C. Wainwright on Alzheimer's candidate
Jun 30We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth
May 10We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
Jan 07Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
Oct 01Revenue & Expenses BreakdownBeta
How Acumen Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -52 | 19 | 0 |
| 30 Sep 23 | 0 | -49 | 17 | 0 |
| 30 Jun 23 | 0 | -46 | 15 | 0 |
| 31 Mar 23 | 0 | -45 | 14 | 0 |
| 31 Dec 22 | 0 | -43 | 13 | 0 |
| 30 Sep 22 | 0 | -38 | 12 | 0 |
| 30 Jun 22 | 0 | -32 | 11 | 0 |
| 31 Mar 22 | 0 | -83 | 9 | 0 |
| 31 Dec 21 | 0 | -101 | 7 | 0 |
| 30 Sep 21 | 0 | -93 | 5 | 0 |
| 30 Jun 21 | 1 | -92 | 3 | 0 |
| 31 Mar 21 | 1 | -32 | 2 | 0 |
| 31 Dec 20 | 1 | -7 | 1 | 0 |
| 31 Dec 19 | 2 | -8 | 1 | 0 |
Quality Earnings: ABOS is currently unprofitable.
Growing Profit Margin: ABOS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ABOS is unprofitable, and losses have increased over the past 5 years at a rate of 8.7% per year.
Accelerating Growth: Unable to compare ABOS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ABOS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: ABOS has a negative Return on Equity (-19.62%), as it is currently unprofitable.